Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.
Vibeke StrandPhillip J MeaseErvant J Maksabedian HernandezBradley S StolshekLyrica X H LiuDavid H CollierGregory KricorianJoseph F MerolaPublished in: RMD open (2021)
Patients receiving etanercept monotherapy or MTX+ etanercept reported greater improvements from baseline in several PROs compared with those receiving MTX monotherapy. PROs should be incorporated in discussions between patients and clinicians regarding their treatment choices as they can help determine which treatments are more beneficial in patients with PsA.
Keyphrases
- patient reported outcomes
- combination therapy
- rheumatoid arthritis
- open label
- rheumatoid arthritis patients
- ankylosing spondylitis
- end stage renal disease
- juvenile idiopathic arthritis
- prostate cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- palliative care
- clinical trial
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- study protocol
- high dose